Medtronic Touts FDA Approval and Launch of Two New CRT Quadripolar Leads

Newly FDA approved, additional Attain Performa® Quadripolar Leads deliver more options so physicians can optimize delivery of Cardiac Resynchronization Therapy

Medtronic, Inc.is announcing U.S. FDA approval and commercial launch of two additional Attain Performa® left ventricular (LV) quadripolar leads, which can be paired with the Medtronic Viva® Quad XT and Viva® Quad S cardiac resynchronization therapy defibrillators (CRT-D) to treat patients with heart failure.

Background

Quadripolar leads help physicians optimize cardiac resynchronization therapy and these two additions to the Attain Performa lead portfolio, the S-shape and Straight leads, are designed to accommodate patients’ varying vessel sizes and curvatures to enhance successful lead placement.

FDA approval for the additional quadripolar leads follows the August 2014 approval of the Attain Performa Model 4298 Dual Cant quadripolar lead. All three leads were studied in the multicenter Attain Performa Quadripolar Lead Clinical Study, involving more than 1,200 patients. Results featured at the 2014 American Heart Association Scientific Session demonstrate an excellent implant success rate (97.6 percent), and show that CRT with the Attain Performa family of LV quadripolar leads is associated with a low complication rate, and low, stable pacing capture thresholds (PCTs) through six months for all pacing polarities.

Medtronic’s press release points out that the three Attain Performa lead shapes -Dual Cant Model 4298, Straight Model 4398 and S-Shape Model 4598 -were designed to accommodate various anatomies without compromising lead handling or stability. It tells us that with 16 pacing configurations and shorter spacing between the two center electrodes, these quadripolar leads have been shown to reduce the incidence of phrenic nerve stimulation (PNS), a potential issue associated with CRT therapy that results in muscle twitching, hiccups or shortness of breath. Attain Performa leads also include steroid elution on all four electrodes for lower chronic pacing thresholds, designed to contribute to greater device longevity and reduce the likelihood of PNS.

Physician comments

“While optimal lead positioning has been shown to improve CRT response rates, every patient is different, making lead placement and stability a common challenge that can result in nonresponse to therapy,” said George H. Crossley, M.D., F.A.C.C., F.H.R.S., associate professor, Vanderbilt Heart and Vascular Institute in Nashville, Tenn. “Having access to a range of lead shapes that work with one CRT-D system gives physicians the ability to help our heart failure patients, even if their cardiac anatomy is challenging.”

Company comments

“With the two new shapes, the Attain Performa quadripolar lead portfolio gives physicians more options than any other CRT-D system available in the United States,” said David Steinhaus, M.D., vice president and general manager, Heart Failure, and medical director for the Cardiac Rhythm and Heart Failure Business at Medtronic. “We are committed to driving advancements in CRT, and designed these leads to give physicians tools to customize treatment for their patients.”

Source: Medtronic, Inc.

published: December 11, 2014 in: Approval/Clearance, Cardio, Launches / Withdrawals, Medtronic

Leave a Reply

Your email address will not be published. Required fields are marked *

Most read

Latest

^